On January 3, 2023, updates to the U.S. Food and Drug Administration (FDA) risk evaluation and mitigation strategy (REMS) for mifepristone for reproductive health indications went into effect. The FDA has permanently removed the in-person dispensing requirement and added a new pharmacy certification process, which will enable retail pharmacies that meet certain qualifications to dispense ... Read more >

As access to legal abortion in the formal healthcare system becomes more restricted across the United States (U.S.), there has been increased focus on understanding the ways that individuals may seek care outside of the healthcare system, including through self-managed abortion (SMA). SMA refers to any action taken to end a pregnancy outside of the ... Read more >

The highly politicized nature of abortion care in this country can make it difficult for institutions and obstetric providers to thoughtfully remark upon and plan for policy decisions that impact patient care. Individuals at high risk for pregnancy mortality and morbidity have unique needs for reproductive health services, including abortion care. Variations in state and ... Read more >

Historical evidence that fetal red blood cell (RBC) exposure during early spontaneous or induced abortion can cause maternal Rh sensitization is limited. A close reading of these studies indicates that forgoing Rh immunoglobulin administration before 12 weeks gestation is highly unlikely to increase risk of Rh (D) antibody development, and recent studies indicate that fetal ... Read more >

Cesarean scar ectopic pregnancy is a complication in which an early pregnancy implants in the scar from a previous cesarean delivery. This condition presents a substantial risk for severe maternal morbidity and mortality because of challenges in securing a prompt diagnosis. Ultrasound is the primary imaging modality for cesarean scar ectopic pregnancy diagnosis, although a ... Read more >